Innovative study by MEDSIR (Pre-ASCO)
Spain
EFE salud - ASCO 2023: Métodos menos invasivos y una mejor relación con el paciente, retos contra el cáncer.
Yahoo Noticias - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención.
Infobae - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención.
MSN - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención.
Qué pasa - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención.
El Nacional - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención.
United States
EFE comunica - Cancer battle shifts focus to less invasive methods, improved patient care.
Ecuador
El Oriente - La lucha contra el cáncer pone su foco en métodos menos invasivos y una mejor atención
Cuba
La prensa latina - Cancer battle shifts focus to less invasive methods, improved patient care.
PHERGain Study
United States
Newswise - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer.
ASCO daily news - Novel Adapted-Response Clinical Trial Identifies Patients With Early Breast Cancer Who May Benefit From Dual HER2 Blockade Alone Without Chemotherapy.
Yahoo Finances - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
PrNewswire - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Benzinga - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Stark County news - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Investors observers - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Medpage today - Chemo-Free Approach Works in Subset of Patients With HER2+ Early Breast Cancer
Yahoo Deportes - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Yahoo Noticias - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
The San Diego Union Tribune - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Yahoo Deportes - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Head Topics - Terapia a medida puede acabar con omnipresencia de quimio en cáncer de mama
Healio - Strategy may enable some patients with HER2-positive breast cancer to avoid chemotherapy
EMPR - Some Patients With HER2+ Early Breast Cancer Can Safely Forgo Chemotherapy
VYRE Business News Global - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Valley Times-News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
USA Times - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
USA Life Sciences Database - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
US Times Mirror - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Treatment News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Toti.com - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Topio Networks - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Times of the Islands - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Times of San Diego - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Time Bulletin USA - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Wetumpka Herald - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Vicksburg Post - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Tryon Daily Bulletin - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Troy Messenger - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Tidewater News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Tallassee Tribune - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Suffolk News-Herald - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The State Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Stanly News & Press - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Selma Times-Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Roanoke Chowan News Herald - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Post-Searchlight - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Pioneer - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Panolian - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Oxford Eagle - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Interior Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Greenville Advocate - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Farmville Herald - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Demopolis Times - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Coastland Times - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Clemmons Courier - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Clanton Advertiser - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Chillicothe Hometown Voice - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Charlotte Gazette - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Brewton Standard - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Bogalusa Daily News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Atmore Advance - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Andalusia Star-News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
The Advocate-Messenger - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Taylorsville Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Taos News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Sugar House Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Style Magazine - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Spoke - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Southwest Daily News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
South Valley Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
South Salt Lake Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
South Jordan Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Society Magazine - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Smithfield Times - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Shelby County Reporter - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Seeking Alpha - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Sangri Times - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Sandy Journal - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Salisbury Post - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
RSW Living Magazine - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Rivers of Living Water Mission - Home Page - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Prentiss Headlight - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
PR Newswire - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Port Arthur News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Picayune Item - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
PharmaOpportunities - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Orange Leader - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
One News Page Global Edition - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Omaha Magazine - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Norwood Town News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Norfolk & Wrentham News - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Spain
La Vanguardia - Optimizar la terapia del cáncer de mama permite evitar la quimio a un 30 % de pacientes
La Razón - El 30% de las pacientes con cáncer de mama HER2-positivo podría curarse sin recibir quimioterapia
La Vanguardia - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Heraldo de Aragón - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Faro de Vigo - Un ensaio abre a porta para curar tumores agresivos de mama sen quimioterapia
El Periódico - Un ensayo abre la puerta a curar tumores agresivos de mama sin quimioterapia
msn - Optimizar la terapia del cáncer de mama permite evitar la quimio a un 30 % de pacientes
Salud a Diario - Un estudio avanza el fin de la quimioterapia para un alto porcentaje de pacientes con cáncer de mama HER2 positivo
Tribuna Valladolid - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
La nación - Avances contra el cáncer: 40 mil expertos de todo el mundo se reúnen en los EE.UU. para exponer las últimas terapias y descubrimientos
EFE comunica - Optimizar la terapia del cáncer de mama permite evitar la quimio a un 30 % de pacientes
Onda Cero - La terapia que puede sustituir a la quimioterapia en el cáncer de mama
El Mercurio - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Mundo Sano - Cáncer de mama: Optimizar la terapia evita la quimio a un 30% de pacientes
EFE Servicios - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Diario de Navarra - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
El diario.es - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Tribuna de Ávila - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Tribuna de Palencia - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Diario de Almeria - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Diariodecadiz.es- - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Diario de Jerez - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Diario de Sevilla - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
El Día De Córdoba - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Europa Sur - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Granada Hoy - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Huelva Información - La terapia hormonal sumada al fármaco ribociclib reduce el riesgo de recaída en el cáncer de mama
Malagahoy.es - La terapia hormonal sumada al fármaco ribociclib reduce la recaída en el cáncer de mama
EFE Servicios - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
iSanidad - Un estudio presentado en ASCO muestra potencial para el tratamiento sin quimioterapia del cáncer de mama temprano positivo para HER2
Newseuro - La oncología busca reducir los tratamientos y su toxicidad
La Vanguardia - Menos es más: la oncología busca reducir los tratamientos y su toxicidad
Brazil
Veja - Cientistas avançam com tratamento sem quimioterapia em tipo de câncer
R7 - Médicos conseguem eliminar câncer de mama agressivo sem quimioterapia
WH3 - Câncer de mama em estágio inicial pode ser eliminado sem quimioterapia, aponta pesquisa
93 noticias - Novo estudo indica possibilidade de evitar quimioterapia em tratamentos de câncer de mama
Rodonoticias - Médicos conseguem eliminar câncer de mama agressivo sem quimioterapia
Studio Fm - Médicos conseguem eliminar câncer de mama agressivo sem quimioterapia
Surgiu - Médicos conseguem eliminar câncer de mama agressivo sem quimioterapia
Metropoles - Câncer de mama: tratamento sem quimio funciona contra tumor agressivo
Diario do Estado - Estudo aponta eliminação do câncer de mama inicial sem quimioterapia
So noticia Boa - Câncer de mama agressivo pode ser tratado sem quimioterapia, mostra estudo
UK
Healthcare - MEDSIR research closer to ‘the end of chemotherapy’
Cuba
La prensa latina - Adaptive breast cancer therapy may bypass chemotherapy for 30% of patients
La prensa latina - Customized therapy could diminish chemotherapy’s dominance in breast cancer treatment
Switzerland
France
Nouvelles du Monde - Méthodes non invasives dans le cancer et amélioration des soins
EFE France - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
EFE France - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
Germany
Finanzen.net - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Czech Republic
Finanzen.ch - MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer
Mexico
Forbes centroamérica - Ensayo clínico PHERGain con resultados positivos para la terapia del cáncer de mama
Diario de Yucatán - Anticuerpos serían mejores que la quimioterapia
El debate - Dos fármacos combinados aumentan supervivencia libre de progresión en el cáncer de ovario
MSN Mexico - Dos fármacos combinados aumentan supervivencia libre de progresión en el cáncer de ovario
Diario de Yucatán - El ribociclib con terapia hormonal evitaría recaídas de cáncer
El siglo Coahulia - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
El siglo de Durango - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
El siglo de Torreón - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Lado mx - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Lado mx - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
Portal Político Tv - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
800 noticias - La terapia puede acabar con la omnipresencia de la quimio en el cáncer de mama
800 noticias - Terapia a medida puede acabar con omnipresencia de quimio en cáncer de mama
Forbes Mexico - Terapia hormonal sumada al fármaco ribociclib reduce recaída del cáncer de mama
El siglo de Durango- Optimizar terapia de cáncer de mama permite evitar 30% la quimio
Diario de Yucatán - La oncología busca mejorar la calidad de vida
El siglo de Durango - Quimio contra cáncer de mama podría terminar
Dominican Republic
Acento diario - Para evitar la quimio a un 30 % de pacientes: Optimizar la terapia del cáncer de mama
Sabrosa 91.1 - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Canada hd - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Guaya canal digital - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Noticias telemicro - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Tamboril Digital - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
El periodico Do - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Diario Libre - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Por el ojo de la cerradura - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Diario de Salud - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
Argentina
Radio Nacional - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Infobae - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Infobea - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
Paraguay
ABC color - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Colombia
Zona Cero - La terapia hormonal sumada al fármaco ribociclib reduce la recaída del cáncer de mama
Ecuador
El Mercurio - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
La hora - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
Venezuela
Hispano Post - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
La Patilla - La terapia a medida puede acabar con la omnipresencia de la quimio en el cáncer de mama
PALMIRA Study
Spain
Diario Siglo XXI - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
IM Médico Hospitalario - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Murcia.com - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Comunicae - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Diario de la mancha - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Hechos de hoy - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Noticias de salud - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Diario de economia -El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
ABC diario - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Mi nota de prensa - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Girona noticies - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Paper Blog - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Notas de prensa - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
El boletín - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Financial Red - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Cádiz Buenas noticias - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Sevillas buenas noticias - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
Valencia buenas noticias - El mantenimiento de palbociclib no mejora la supervivencia libre de progresión respecto a la terapia endocrina en pacientes con cáncer de mama avanzado HR+/HER2-
United States
The Cancer News- Updates From ASCO – Results From The PALMIRA Study
Medpage today - Studies Question Role of CDK4/6 Inhibitors in First-Line Advanced Breast Cancer
Newswise - MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients
Yahoo Finance - MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients
PR Newswire - MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients
Market Watch -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Benzinga -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Cision -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Morningstar -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
69News -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Salisbury Post -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The outlook -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
One News page -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The democrat -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
FDA Red Watch-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
ExecEdge - Healthcare Edge-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Mazada Pharma Guide-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Bonita & Estero Magazine-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Bradfordville-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Cape coral Living Magazine-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Chilliicothe Hometown Voice-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Connect Iredell-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Cottonwood Heights Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Draper Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Fayetteville Connect-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Franklin Town News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Gulf & main-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Herriman Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Holladay Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Holliston Town News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Hopedale Town News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Midvale Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Milcreek Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Sugar House Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Natick Town News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Norwood Town News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Pioneer-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
South Valley Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Sandy Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
South Salt Lake Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Taos News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Toti.com-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
City Journals -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
West Jordan Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
West Valley City Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Treatment News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
VYRE Business News Global-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Rivers of Living Water Mission-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Taylorsville Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Mississipi Oncology Society-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Omaha Magazine-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Alabama Cancer Congress-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Murray Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Grit Daily-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Mahalsa US-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Bloggers of Heatlh -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
USA Times-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
US Times Mirror -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Industry News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Hattiestburg-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Walnut Creek-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Style Magazine -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Hot News Alerts-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Coastal Today-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
American Talk-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Medway & Millis News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Davis Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Intern Daily-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Society Magazine-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
South Jordan Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Gates County Index-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Chinese Wire-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Times of San Diego-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Chester Country Press-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
WNC Business-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
MB News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Columbia Business Monthly-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Greenville Business Magazine-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Norflok & Wrentham -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Business Class News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Healthcare Today-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Support for Stepdad-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Escaping Pleasure Trap-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Beauregard News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Stock Watcher-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Harlan Enterprise-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Forefront Media News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Latin Business Today-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Charlotte Gazette-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Bambu Up-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The prentiss Headlight-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Windsor Weekly-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Washington City Paper-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Claiborne Progress-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Alabama Now-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Southwest Daily Times-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The demopolis Times-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Kenbridge Victoria Dispatch-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Panolian-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Clemmons Courier-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Luverne Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Lowndes Signal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Middlesboro News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Jessamine Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Interior Journal -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Cordele Dispatch-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Discovery Bit-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Americus Times-Recorder-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Time Bulletin USA-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
News Blaze-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Tallassee Tribune-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Tidewater News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Davie County Enterprise Record-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Leesville Daily Reade-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Atmore Advance-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Roanoke Chowan News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Tyron Daily Bulletin-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Post-Searchlight-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Clanton Advertiser-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Greenville Advocate-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Selma Times-Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Canadian Insiders-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Bogalusa Daily News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Brewton Standard-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Farmville Herald-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Stanly News & Press-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Wetumpka Herald-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The advocate-Messenger-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Iroton Trubune -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Star-News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Valley Times-News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Oxford Eagle-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Winchester Sun-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Orange Leader-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Washington Daily News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Suffol News Herald-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Elizabethton Star-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Spoke-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Leader Publications-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Boreal Community Media-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The troy messenger-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Picayune Item-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
L'observateur-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Austin Daily Herald-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Smithfield Times-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Coastland Times-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
American Press-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
The Vicksburg Post-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Shelby County Reporter-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Mongolia state live -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Albert Lea Tribune-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
State Journal-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Jewish Link-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Le Grange Daily News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Port Arthur The News-MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Japan
Medical nikkeibp - パルボシクリブ治療を受けたHR陽性乳癌の2次治療でのパルボシクリブ継続投与はPFSを改善しない【ASCO 2023】
Medical nikkeibp - パルボシクリブ治療を受けたHR陽性乳癌の2次治療でのパルボシクリブ継続投与はPFSを改善しない【ASCO 2023】
India
Sangri Times - -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Australia
About Pain - -MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2-
Oncoclínicas & MEDSIR at ASCO
Brazil
THmais - Oncoclínicas levará comitiva de 120 brasileiros para congresso sobre câncer nos EUA.
Folha de S.Paulo - Oncoclínicas levará comitiva de 120 brasileiros para congresso sobre câncer nos EUA.
Acessa - Oncoclínicas levará comitiva de 120 brasileiros para congresso sobre câncer nos EUA.
Conexao jornalismo - Oncoclínicas levará comitiva de 120 brasileiros para congresso sobre câncer nos EUA.
Saúde - Grupo Oncoclínicas apresenta estudos no maior congresso de oncologia do mundo.
Let's go Bahia - Asco 2023: o que esperar da edição deste ano do maior congresso de oncologia do mundo
Ao vivo de Brasilia - RIBOCICLIBE REDUZ EM 25% O RISCO DE RETORNO DO CÂNCER DE MAMA MAIS COMUM
